目的 探討益心舒膠囊聯(lián)合鹽酸胺碘酮片治療非瓣膜性心房顫動的療效。方法 選取2023年6月—2024年8月在石家莊市第三醫(yī)院就診的共計102例非瓣膜性心房顫動患者，按照隨機(jī)數(shù)字表法將所有患者分為對照組和治療組，每組各51例。對照組口服鹽酸胺碘酮片，1片/次，3次/d。治療組在對照組基礎(chǔ)上口服益心舒膠囊，3次/d,3粒/次。兩組的療程為2個月。比較兩組患者的治療效果、房顫癥狀、心功能指標(biāo)和血清指標(biāo)水平。結(jié)果 治療組的總有效率明顯比對照組高，組間比較差異顯著（96.08%vs 84.31%,P<0.05）。治療后，兩組的心房顫動發(fā)作頻率和持續(xù)時間均減少（P<0.05），且治療組心房顫動發(fā)作頻率和持續(xù)時間低于對照組（P<0.05）。治療后，兩組的左房射血分?jǐn)?shù)（LAEF）、左心耳排空速度（VLAA）均升高，左房容積指數(shù)（LAVI）均降低（P<0.05）；治療組的LAEF、VLAA高于對照組，LAVI低于對照組（P<0.05）。治療后，兩組的血清血管細(xì)胞黏附分子1(VCAM-1)、高遷移率族蛋白B1(HMGB-1)、內(nèi)皮素-1(ET-1)水平均降低P<0.05），治療組的血清VCAM-1、HMGB-1、ET-1水平均低于對照組（P<0.05）。結(jié)論 益心舒膠囊聯(lián)合鹽酸胺碘酮片可提高非瓣膜性心房顫動的臨床療效，顯著減輕心房顫動癥狀，改善心功能，減輕血管內(nèi)皮功能。

Objective To investigate the clinical efficacy of Yixinshu Capsules combined with Amiodarone Hydrochloride Tablets in treatment of non valvular atrial fibrillation. Methods A total of 102 patients with non valvular atrial fibrillation who visited The Third Hospital of Shijiazhuang from June 2023 to August 2024 were divided into control group and treatment group according to the random number table method, with 51 cases in each group. Patients in the control group took Amiodarone Hydrochloride Tablets orally, 1 tablets/time, 3 times daily. Patients in the treatment group were po administered with Yixinshu Capsules on the basis of the control group, 3 times daily, 3 capsules/time. The course for two groups was 2 months. The treatment efficacy, atrial fibrillation symptoms, cardiac function indicators, and serum indicator levels between two groups of patients were compared. Results The total effective rate of the treatment group was significantly higher than that of the control group, and the difference between the groups was significant（96.08% vs 84.31%, P＜0.05）. After treatment, the frequency and duration of atrial fibrillation in two groups were decreased（P＜0.05）, and the frequency and duration of atrial fibrillation in the treatment group were lower than those in the control group（P＜0.05）. After treatment, LAEF and VLAA of the two groups were increased, while LAVI was decreased（P＜0.05）. LAEF and VLAA of the treatment group were higher than those of the control group, but LAVI was lower than that of the control group（P＜0.05）. After treatment, the levels of serum VCAM-1, HMGB-1, and ET-1 in two groups were decreased（P＜0.05）, and the levels of VCAM-1, HMGB-1, and ET-1 in the treatment group were lower than those in the control group（P＜0.05）. Conclusion The combination of Yixinshu Capsules and Amiodarone Hydrochloride Tablets can improve the efficacy of non valvular atrial fibrillation, significantly reduce atrial fibrillation symptoms, improve heart function, and alleviate vascular endothelial function.

R972

河北省醫(yī)學(xué)科學(xué)研究課題(20241920)